SPL.AX - Starpharma Holdings Limited

ASX - ASX Delayed price. Currency in AUD
1.3875
+0.0275 (+2.0221%)
At close: 3:59PM AEDT
Stock chart is not supported by your current browser
Previous close1.3600
Open1.3700
Bid1.4250 x 703400
Ask1.3250 x 22100
Day's range1.3500 - 1.3900
52-week range0.6370 - 1.4750
Volume203,069
Avg. volume574,758
Market cap514.09M
Beta1.05
PE ratio (TTM)63.07
EPS (TTM)0.02
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.99
  • Business Wire2 months ago

    Starpharma: Successful VivaGel® Phase 3 Results and NDA Planned for rBV

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data. Starpharma intends to submit a marketing application to the FDA for VivaGel® BV for prevention of rBV based on these positive results.

  • Business Wire4 months ago

    Starpharma Sells Agrochemicals Business to Agrium for $35M

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. This business is independent of Starpharma’s DEP® and VivaGel® products and related intellectual property portfolios.

  • Business Wire6 months ago

    Ansell Launches VivaGel® Condom in Canada

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) is pleased to announce the VivaGel ® condom has been launched in Canada by Ansell (ASX:ANN) under the LifeStyles ® ...

  • Business Wire9 months ago

    VivaGel® BV granted QIDP and Fast Track designation by US FDA

    MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA). QIDP and Fast Track designations were granted independently for both the VivaGel® BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel® BV to address that need for both treatment and prevention of recurrent BV, markets estimated to be worth in excess of US$1 billion globally.

  • noodls10 months ago

    Starpharma receives $3.5M R&D tax incentive refund

    Starpharma receives $3.5M R&D tax incentive refund Melbourne, Australia; 22 December 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $3.5M of R&D ...